Title: Rare diaphragmatic tumor mimicking liver mass

Author: Shalini Thapar, Arvind Ahuja, Archana Rastogi

Name of Journal: *World Journal of Gastrointestinal Surgery*

ESPS Manuscript NO: 3076

Reviewer's comments and authors' answers

The authors report a case entitled "Rare Diaphragmatic Tumor Mimicking Liver Mass– The eyes see what the mind knows... The diagnosis is a low-grade fibromyxoid sarcoma.

Major concerns: While the crux of the case lies in its diagnosis, pathological description of this case is quite suboptimal.

Pathological description has been elaborated.

In fact, the entity has not been correctly termed. According to the WHO classification, it is low-grade fibromyxoid sarcoma that has a spectrum including hyalinizing spindle cell sarcoma with giant rosettes. It is a definite tumor entity with distinct genetic signature. The authors should necessarily make this major correction.

Our case was a classical low grade fibromyxoid sarcoma with characterstic histopathological features and not the variant. Although genetic studies were not done in this patient

LGFMS is different from a myxofibrosarcoma that should be discussed in the differential diagnosis.

Detailed discussion on differential diagnosis has been added in discussion part.

The authors need to discuss pathological findings in more detail to substantiate diagnosis of LGFMS at this relatively uncommon location. Vimentin is positive in most sarcomas, quite a few carcinomas and some lymphomas. It is non-specific in this particular case.

The details of the panel of immunohistochemistry which was performed has been added.

The authors have acknowledged that Fibromyxoid sarcoma shows characteristic histopathological and immunochemistry features. Kindly clarify.

Added in the differential diagnosis

Recently, MUC4 has been described as an important IHC marker in cases of LGFMS. It would be worthwhile to know the results of this marker in their case? Else, a mention with a suitable reference is important. LFGMS also has a specific genetic transcript FUS-CREB3L2 and FUS-CREB3L1.

MUC 4 was not done in this case as we don't have in our lab. However, the specific transcript has been mentioned in discussion.

Are these tumors chemo sensitive, kindly clarify management options.

These tumors have been found to be poor responders to chemotherapy. Latest literature about the role of chemotherapy and drug used has been added to the discussion part.